Hemosol secures $13 million loan
This article was originally published in Clinica
Executive Summary
Hemosol, the Toronto-based blood substitute company, has eased its cash crisis by securing a Can$20m ($12.8m) loan from the Bank of Nova Scotia. The company's share value was hit in mid-September when it revealed that it would need more cash to fund activities beyond the end of this year.